Electronic ISSN 2287-0237



  1. Zimmerman, FH, Cameron A, Fisher L, et al. Myocardialinfarction in young adults: Angiographic characterization, riskfactors and prognosis (Coronary Artery Surgery Study Registry).JACC1995;26(3):654-61.
  2. Guipeng A, Zhongqi Du, Xiao M, et al. Risk factors for long-termoutcome of drug-eluting stenting in adults with early-onsetcoronary artery disease. Inter J Medical Sciences2014;11(7):721-5.doi: 10.7150/ijms.8718
  3. Tungsubutra W, Treesukosol D, Buddhari W, et al. Acutecoronary syndrome in young adults: the Thai ACS Registry.J Med Assoc Thai 2007; 90(Suppl1):81-90.
  4. Wong CP, Loh SY, Loh KK, et al. Acute myocardial infarction:Clinical features and outcomes in young adults in Singapore.World Cardiol J 2012; 496:206-10.
  5. Chen TS, Incani A, Butler TC, et al. The demographic profileof young patients (
  6. Narongchai P, Narongchai S. Study of the normal internalorgan weights in Thai population. J Med Assoc Thai2008;91(5):747-53.
  7. Egred M, Viswannathan G, Davis K. Myocardial infarctionin young adults. Postgrad Med J 2005;81:741-5. doi: 10.1136/pgmj.2004.027532
  8. Hill SF, Sheppard MN. Non-atherosclerotic coronary arterydisease associated with sudden cardiac death. Heart 2010;96:1119-25.
  9. Gorenek B, Lundqvist CB, Terradellas JB, et al. Cardiacarrhythmias in acute coronary syndromes: The joint task forceEHRA, ACCA, and EAPCI task force. EuroIntervention2015;10(9):1095-108. doi: 10.4244/EIJY14M08_19
  10. FitzGerald GA. COX-2 and beyond: approaches toprostaglandin inhibition in human disease. Nat Rev DrugDiscov 2003;2:879-90.
  11. FitzGerald GA. Coxibs and cardiovascular disease. N Engl JMed 2014;351(17):209-11.
  12. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascularsafety of celecoxib, naproxen, or ibuprofen for arthritis. NEngl J Med 2016; 375(26):2519-29.
  13. De Vecchis R, Bald C, Di Biase G, et al. Cardiovascular riskassociated with celecoxib or etoricoxib: a meta-analysis ofrandomized controlled trials which adopted comparison withplacebo or naproxen. Minerva Cardioangiol 2014; 62:437-48.
  14. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascularsafety of non-steroidal anti-inflammatory drugs: networkmeta-analysis. BMJ 2011;342:c7086 doi:10.1136/bmj.c7086
  15. Veerakul G, Lapanun W, Sindhuwanna U, et al. Acutemyocardial infarction development after COX-2 inhibitor drugadministration: a report of two cases. Intern Med J Thai 2005;21(4):276-81.
  16. Lenzer J. FDA advisers warn: COX 2 inhibitors increase riskof heart attack and stroke. BMJ 2005; 330(26):440.
  17. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase Inhibitionand Cardiovascular Risk, special report. Circulation2005;112:759-70.
  18. Noble J, Bourassa MG, Petitclerc R, et al. Myocardial bridgingand milking effect of the left anterior descending coronaryartery: normal variant or obstruction? Am J Cardiol1976;37:993-9.
  19. Kramer JR, Kitazume H, Proudfit WL, et al. Clinical significanceof isolated coronary bridges: benign and frequent conditioninvolving the left anterior descending artery. Am Heart J1982;103:283-88.
  20. Leschka S, Koepfli P, Husmann L, et al. Myocardial bridging:Depiction rate and morphology at CT coronary angiography:Comparison with conventional coronary angiography. Radiology2008;246:754-62.
  21. Lee SS, Wu TL. The role of the mural coronary artery inprevention of coronary atherosclerosis. Arch Pathol1972;93:32-5.
  22. Kramer JR, Kitazume H, Proudfit WL, et al. Clinicalsignificance of isolated coronary bridges: benign and frequentcondition involving the left anterior descending artery. AmHeart J 1982;103:283-88.
  23. Juillière Y, Berder V, Suty-Selton C, et al. Isolated myocardialbridges with angiographic milking of left anterior descendingcoronary artery: a long-term follow-up study. Am Heart J1995; 129:663-5.
  24. Bauters C, Chmait A, Tricot O, et al. Coronary thrombosisand myocardial bridging. Circulation 2002;105(1):130.
  25. Bergmark BA, Galper BZ, Shah AM, et al. Myocardial bridgingin a man with non–ST-elevation myocardial infarction.Circulation 2015 131(11):e373-e374
  26. Arjomand H, AlSalman J, Azain J, et al. Myocardial bridgingof left circumflex coronary artery associated with acutemyocardial infarction. J Invasive Cardiol 2000;12(8):431-4.
  27. Tio RA, Ebels T. Ventricular septal rupture caused bymyocardial bridging. Ann Thoracic Surg 2001;72:1369-70.
  28. Den Dulk K, Brugada P, Braat S, et al. Myocardial bridgingas a cause of paroxysmal atrioventricular block. J Am CollCardiol 1983;1: 965–9.
  29. Feld H, Guadanino V, Hollander G, et al. Exercise-inducedventricular tachycardia in association with a myocardialbridge. Chest 1991;99:1295-6.
  30. MCutler D, Wallace JM. Myocardial bridging in a youngpatient with sudden death. Clin Cardiol 1997;20:581-3.
  31. Hostiuc S, Rusu MC, Hostiu M, et al. Cardiovascularconsequences of myocardial bridging: A meta- analysis andmeta-regression. Sci Rep 2017;7:14644. DOI:10.1038/s41598-017-13958-0.
  32. Ishikawa Y, Kawawa Y, Kohda E, et al. Significance of theanatomical properties of a myocardial bridge in coronary heartdisease. Circ J 2011;75:1559-66.
  33. Bourassa MG, Butnaru A, Lesperance J, et al. Symptomaticmyocardial bridges: overview of ischemic mechanisms andcurrent diagnostic and treatment strategies. J Am CollCardiol 2003;41:351–9.
  34. Klues HG, Schwarz ER, vom Dahl J, et al. Disturbedintracoronary hemodynamics in myocardial bridging: earlynormalization by intracoronary stent placement. Circulation1997; 96:2905-13.
  35. Risse M, Weiler G. Coronary muscle bridge and its relationsto local coronary sclerosis, regional myocardial ischemia andcoronary spasm: a morphometric study [German]. Z Kardiol1985;74:700–5.
  36. Masuda T, Ishikawa Y, Akasaka Y, et al. The effect ofmyocardial bridging of the coronary artery on vasoactive agentsand atherosclerosis localization. J Pathol 2001;193: 408-14.
  37. Ishii T, Asuwa N, Masuda S, et al. Atherosclerosis suppressionin the left anterior descending coronary artery by the presenceof a myocardial bridge: an ultrastructural study. Mod Pathol1991;4:424-31.
  38. Teragawa H, Fukuda Y, Matsuda K, et al. Myocardial BridgingIncreases the risk of Coronary Spasm. Clin Cardiol2003;26:377-83.
  39. Piepoli MF, Hoes AW, Agewall S, et al. 2016 EuropeanGuidelines on cardiovascular disease prevention in clinicalpractice: The Sixth Joint Task Force of the European Societyof Cardiology and Other Societies on Cardiovascular DiseasePrevention in Clinical Practice (constituted by representativesof 10 societies and by invited experts). Eur Heart J 2016;37(29):2315-81.
  40. Shapiro M, Fazio S. Familial hypercholesterolemia: use ofregistries, biobanks, and cohort studies to improve itsdiagnosis and management in non-western populations. BKKMed J 2018; 14(1):63-8.
  41. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: areport of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines. Circulation2014;129(25suppl2):S49-73.
  42. Sritara P, Cheepudomwit S, Chapman N, et al. Twelve yearchanges in vascular risk factors and their associations withmortality in a cohort of 3,499 Thais: the electricity generatingauthority of Thailand study. Int J Epidemiol 2003;32:461-8.
  43. World Health Organization. Prevention of cardiovasculardisease: pocket guidelines of assessment and management ofcardiovascular risk (WHO/ISH Cardiovascular Risk PredictionCharts for WHO epidemiological sub-regions AFR D andAFR E), Geneva 2007, (Accessed at January 15, 2019 athttps://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf?ua=1).
  44. Veerakul G, Khajornyai A, Wongkasia S, et al. Predicting andpreventing cardiovascular events in asymptomatic patients: a10-year prospective study. BKK Med J 2017;13:1-12.
  45. Knot UN, Khot MB, Bajzer CT, et al. Prevalence ofconventional risk factors in patients with coronary heartdisease. JAMA 2003;290(7);898-904.
  46. Zhong Z, Liu J, Li B et al. Serum lipid profiles in patientswith acute myocardial infarction in Hakka population insouthern China. Lipids Health Dis 2017;16(1):246. doi:10.1186/s12944-017-0636-x.
  47. Mazurek T, Zhnag L, Zalewski A, et al. Human epicardialadipose tissue is a source of inflammatory mediators. Circulation2003;108:2460-6.
  48. Meenakshi K, rajendran M, Srikumar S, et al. Epicardial fatthickness: A surrogate marker of coronary artery disease,assessment by echocardiography. Indian Heart J 2006;68:336-41.
  49. Hwang IC, Park HE, Choi SY. Epicardial adipose tissuecontributes to the development of non-calcified coronaryplaque: a 5-year computed tomography follow-up study. JAtheroscler Thromb 2017;24:262-74. doi:10.5551/jat.36467.
  50. Kaikita K. Epicardial adipose tissue as a predictor for thedevelopment of Non-calcified coronary plaque. J AtherosclerThromb 2017;24:254-5. doi: 10.5551/jat.ED062.